Sartorius Stedim Biotech Partners with Nanotein Technologies to Boost Cell Therapy Manufacturing
Tuesday, August 12, 2025
Sartorius Stedim Biotech, a supplier to the biopharmaceutical industry, has formed a partnership with Nanotein Technologies, a company developing next-generation immune cell activation reagents. As part of the agreement, Sartorius will invest up to 3 million US dollars for a minority shareholding in Nanotein to support the commercialisation and joint development of solutions based on the NanoSpark® platform.
Under an exclusive distribution arrangement, Sartorius will provide Nanotein’s main products to customers worldwide, including the NanoSpark® STEM-T Soluble T Cell Activator and NanoSpark® GROW-NK Soluble Activator. These reagents are designed to increase both the expansion and yield of T cells and natural killer (NK) cells, which are essential in various cell therapy applications such as CAR-T and NK-based cancer treatments.
Effective cell therapy production begins with immune cell activation to stimulate expansion and generate large quantities of high-quality cells. This process can be hindered by challenges such as dependence on feeder cells or inconsistent yields. Nanotein’s soluble activators are intended to address these issues by improving cell expansion, enhancing cell quality, and offering a feeder-free option for NK cell activation and growth.
The partnership also includes plans to develop additional products using the NanoSpark® platform to serve the growing cell and gene therapy markets.
Source: businesswire.com
